- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07625462
Hearing and Brain Development Cohort in Children and Adolescents (HBD-Cohort)
3. juni 2026 opdateret af: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Longitudinal Cohort Study of Hearing and Brain Development in Children and Adolescents With Hearing Loss Across Different Hearing Management Pathways and in Normal-Hearing Controls
This bidirectional observational cohort study aims to establish a Hearing and Brain Development (HBD) cohort in children and adolescents with hearing loss across different hearing management pathways, including hearing aid fitting, cochlear implantation, auditory brainstem implantation, gene therapy, and follow-up without intervention, as well as in a normal-hearing control group.
Participants will undergo longitudinal assessments of hearing, speech, language, neurodevelopment, and multimodal brain function.
Studieoversigt
Status
Rekruttering
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Anslået)
5000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Yun Li
- Telefonnummer: +86-21-53314064
- E-mail: liyuncmm@126.com
Studiesteder
-
-
-
Shanghai, Kina, 200011
- Rekruttering
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
-
Kontakt:
- Yun Li
- Telefonnummer: +86-21-53314064
- E-mail: liyuncmm@126.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Ja
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
The study population consists of children and adolescents aged 0 to 18 years who are evaluated and/or managed at the Department of Otolaryngology-Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.
The cohort includes participants with hearing loss across different hearing management pathways, including hearing aid fitting, cochlear implantation, auditory brainstem implantation, gene therapy, and follow-up without intervention, as well as a normal-hearing control group.
Beskrivelse
Inclusion Criteria:
- Age no more than 18 years.
- For the HA/CI/ABI/GT/FU groups: behavioral or pure-tone hearing threshold >=20 dB HL, or air-conduction ABR >=35 dB nHL; For the normal-hearing control group: participants diagnosed as normal hearing by experienced physicians.
Exclusion Criteria:
- Inability to cooperate with study testing procedures.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
HA
Participants suitable for unilateral or bilateral hearing aid(s) fitting, without any other intervention methods (cochlear implantation, gene therapy treatment, auditory brainstem implantation, etc.).
|
|
CI
Participants suitable for unilateral or bilateral cochlear implantation, without gene therapy treatment or auditory brainstem implantation.
|
|
ABI
Participants suitable for unilateral or bilateral auditory brainstem implantation.
|
|
GT
Participants suitable for gene therapy treatment.
|
|
FU
Participants with hearing loss who do not receive any intervention.
|
|
NH Control
Participants with normal hearing who are enrolled as healthy controls.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Categories of Auditory Performance-II Score
Tidsramme: From baseline to 24-month follow-up
|
The Categories of Auditory Performance-II scale will be used to assess auditory performance.
Scores range from 0 to 9, with higher scores indicating better auditory performance.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Speech Intelligibility Rating Score
Tidsramme: From baseline to 24-month follow-up
|
The Speech Intelligibility Rating scale will be used to assess speech intelligibility.
Scores range from 1 to 5, with higher scores indicating better speech intelligibility.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in MRI-derived Brain Development Deviation Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The MRI-derived Brain Development Deviation Composite Score will be calculated from pre-specified multimodal brain magnetic resonance imaging measures using age-adjusted normative models.
All pre-specified MRI measures will be combined into a single standardized composite score before analysis.
The score summarizes the magnitude of deviation from age-expected brain development.
Higher values indicate greater deviation from age-expected brain development.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Parent-Child Interaction Quality Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The Parent-Child Interaction Quality Composite Score will be used to assess parent-child interaction quality based on a pre-specified observational coding scheme.
The composite score summarizes overall interaction quality during recorded parent-child interaction tasks.
Higher scores indicate better parent-child interaction quality.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Griffiths Mental Development Scales General Development Score
Tidsramme: From baseline to 24-month follow-up
|
The Griffiths Mental Development Scales will be used to assess general developmental level.
The general development score reflects overall developmental functioning across multiple developmental domains.
Higher scores indicate better general developmental functioning.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Ages and Stages Questionnaires: Social-Emotional, Second Edition Total Score
Tidsramme: From baseline to 24-month follow-up
|
The Ages and Stages Questionnaires: Social-Emotional, Second Edition will be used to assess social-emotional development.
Total scores vary by age-specific form, with higher scores indicating greater social-emotional concern.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
|
Change in Adaptive Behavior Assessment System, Second Edition General Adaptive Composite Score
Tidsramme: From baseline to 24-month follow-up
|
The Adaptive Behavior Assessment System, Second Edition will be used to assess adaptive behavior.
The General Adaptive Composite score summarizes overall adaptive functioning across daily living, communication, social, and practical adaptive skill areas.
Higher scores indicate better adaptive functioning.
Change is calculated as the value at follow-up minus the baseline value.
|
From baseline to 24-month follow-up
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Hao Wu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
- Studiestol: Hao Wu, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
20. maj 2026
Primær færdiggørelse (Anslået)
31. december 2030
Studieafslutning (Anslået)
31. december 2030
Datoer for studieregistrering
Først indsendt
20. maj 2026
Først indsendt, der opfyldte QC-kriterier
3. juni 2026
Først opslået (Faktiske)
4. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
4. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. juni 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HBD-Cohort
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-delingstidsramme
The IPD will be available beginning 6 months after study completion.
IPD-delingsadgangskriterier
Detailed data are available upon reasonable request.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .